By rray, 22 February, 2024 Check adherence inhaler technique and possible interfering comorbidities Target dyspnea sx w additional tx consider switching inhaler device or molecules Implement or escalate non pharm tx Investigate and treat other causes of dyspnea Mitigate risks
By rray, 22 February, 2024 Continue short acting BD for sx rescue SAMA ipratropium MDI NEB SABA albuterol levalbuterol MDI NEB for all pts
By rray, 22 February, 2024 If on single LABA or LAMA Use LAMA LABA combo SABA SAMA combos more effective than mono tx A LABAs and LAMAs improve dyspnea reduce exac rate A LAMAs reduce exac A and hospitalizations B more than LABAs combos more effective than mono tx B nbsp nbsp LAMA
By rray, 22 February, 2024 Treatments w no or uncertain benefits oral steroids C antitussives C vasodilators B drugs for primary pulm HTN B mepolizumab benralizumab dupilumab nedocromil leukotriene modifiers infliximab immunostimulants beta blockers if no CV indication for use simv
By rray, 22 February, 2024 Follow COVID 19 mitigation strategies and test for SARS CoV 2 if warranted e g new or worsening resp sx fever loss of taste and or smell If SARS CoV 2 pos continue usual COPD meds
By rray, 22 February, 2024 Consider shielding measures e g masking social distancing handwashing to prevent exac in winter months
By rray, 22 February, 2024 Evaluate and treat comorbidities CVD skeletal muscle dysfxn metabolic syndrome osteoporosis depression anxiety lung CA